Drug intelligence / Profile preview

KKM-191-D

Development stage: Unknown
Lead developer: Genewon Science
Modality: Small Molecules
Administration: Oral, Injection

Overview

KKM-191-D is an incrementally modified small molecule drug (IMD) being developed by Genuone Science for the treatment of type 2 diabetes. As an "improved drug" (개량신약), it is a modified version of an existing therapeutic approach, designed to offer clinical benefits such as enhanced efficacy, improved safety, or better patient compliance compared to the original reference product. The drug is currently in Phase I clinical trials, where it is being evaluated for safety, tolerability, and pharmacokinetic properties in human subjects.

Beyond the preview

Go deeper on KKM-191-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KKM-191-D.

Explore the full profile